News 10.04.2026 New research from Zurich shows that the gut microbiome may have an impact on cancer immunotherapy, giving patients who did not initially respond to treatment a second chance. In recent years, cancer immunotherapy has been one of the greatest advances in the field of oncology. Unlike chemotherapy and radiotherapy, this treatment...
News 07.04.2026 ETH Professor Emeritus Ruedi Aebersold, together with John Yates from the Scripps Research Institute in La Jolla, USA, and Matthias Mann from the Max Planck Institute in Martinsried, Germany, has been honoured with the prestigious Canada Gairdner International Award. The three scientists founded and shaped modern proteomics research. See full article:...
News 01.04.2026 Schlieren, Zurich — Surgical Fusion Technologies has received a 1.2 million Swiss franc grant from Innosuisse to further develop its surgical method for sports medicine. The medtech company uses an ultrasound generator to create bioresorbable anchors that connect soft tissue to bone. The Swiss innovation agency Innosuisse is supporting Surgical Fusion...
News 31.03.2026 A new peer-reviewed publication reports 1-year results from a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial evaluating denovoSkin™ in reconstructive surgery in patients of all ages. The study evaluated denovoSkin™ against autologous split-thickness skin grafts (STSG) in 23 patients with full-thickness skin defects requiring planned elective reconstruction. According to...
News 23.03.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and...